Sutro BiopharmaFRA:S090 -1.56%41 Current Ratio is 3.12 as of Mar. 2026, which is 31% below its 10-year median of 4.50. GuruFocus rates FRA:S090 with a GF Score™ of 41/100 and a GF Value™ of €10.30 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Sutro Biopharma ranks worse than 56.98% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sutro Biopharma's current ratio for the quarter that ended in Mar. 2026 was 3.12.
Sutro Biopharma has a current ratio of 3.12. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Sutro Biopharma's Current Ratio or its related term are showing as below:
FRA:S090'
s Current Ratio Range Over the Past 10 Years
Min: 0.8 Med: 4.5 Max: 12.78
Current: 3.12
During the past 10 years, Sutro Biopharma's highest Current Ratio was 12.78. The lowest was 0.80. And the median was 4.50.
FRA:S090's Current Ratio is ranked worse than 56.98% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs FRA:S090: 3.12
Sutro Biopharma (FRA:S090) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sutro Biopharma Current Ratio Related Terms
Sutro Biopharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S090 vs NGNE, OCGN, CBIO: Current Ratio Comparison
For the Biotechnology subindustry, Sutro Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (FRA:S090) has a Current Ratio of 3.12 as of Mar. 2026. This is 31% below median its historical median of 4.50. Over the past decade, Sutro Biopharma's Current Ratio has ranged from 0.80 to 12.78. According to the industry distribution chart, Sutro Biopharma ranks #804 out of 1411 companies in the Biotechnology industry, placing it in the top 57%.
Is Sutro Biopharma's Current Ratio too high?
Sutro Biopharma's current Current Ratio of 3.12 is 31% below median its 10-year median of 4.50. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 12.78. The Biotechnology industry median Current Ratio is 3.91. Sutro Biopharma's value of 3.12 is 20.2% below this industry median. Based on the distribution chart, Sutro Biopharma ranks #804 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Current Ratio compare to NGNE and OCGN?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #804 out of 1411 companies for Current Ratio. This places Sutro Biopharma in the lower half of its industry. The industry median Current Ratio is 3.91. Sutro Biopharma's value of 3.12 is 20.2% below this benchmark. Historically, Sutro Biopharma's own Current Ratio has ranged from 0.80 to 12.78 over the past decade. While the company's 10-year median is 4.50 vs. the industry median of 3.91, Sutro Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sutro Biopharma's current Current Ratio of 3.12 is 20.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Current Ratio is 3.12, which is 31% below median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (FRA:S090) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.30, compared to a current price of €25.20 — trading 144.7% above its estimated fair value. The current Current Ratio is 3.12, which is 31% below median its 10-year median of 4.50 and 20.2% below the Biotechnology industry median of 3.91. Sutro Biopharma's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sutro Biopharma (FRA:S090), the current Current Ratio is 3.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (FRA:S090) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of €25.20 is trading 144.7% above its estimated GF Value™ of €10.30.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for FRA:S090:
Current Ratio: 3.12 (31% below median its 10-year median of 4.50)
GF Value™: €10.30 vs. price of €25.20 (144.7% above fair value)
Industry Position: 20.2% below the Biotechnology median (#804 of 1411)
No single metric tells the full story. See the FRA:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
41GF Score
Get the complete analysis for FRA:S090
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S090 has been successfully added to your 
